Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL19209935 | 1.00 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL584582 | 1.00 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL21331899 | 1.00 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL2013770 | 0.94 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL7582135 | 0.94 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL15813193 | 0.93 | PTGS1 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL2594368 | 0.93 | PTGS1 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL19715307 | 0.93 | PTGS1 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL8080341 | 0.92 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL163442 | 0.92 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491259-B2 | Anti-variable MUC1* antibodies and uses thereof | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-12-09 | — | — | US | claimed |
| EP-4408990-A2 | ENGINEERED LIPASE ENZYMES, MANUFACTURE AND USE THEREOF | Anagram Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | claimed |
| WO-2023056469-A2 | ENGINEERED LIPASE ENZYMES, MANUFACTURE AND USE THEREOF | SYNSPIRA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| US-10022319-B2 | Stabilized antibody-containing liquid formulations | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-07-17 | — | — | US | claimed |
| CN-107208101-A | Cause the gene through modification that parthenocarpy is beared fruit | 瑞克斯旺种苗集团公司 | 2017-09-26 | — | — | CN | claimed |
| US-20260015631-A1 | TYPE I-D CRISPR-ASSOCIATED TRANSPOSASE AND TYROSINE RECOMBINASE TRANSPOSON SYSTEMS | BROAD INST INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4612130-A1 | POLYMORPHIC FORMS OF A SOLUBLE EPOXIDE HYDROLASE INHIBITOR AND FORMULATIONS THEREOF | Eicosis, LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3714902-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSORBATE | LEK PHARMACEUTICALS (SI) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024163717-A1 | TYPE I-D CRISPR-ASSOCIATED TRANSPOSASE AND TYROSINE RECOMBINASE TRANSPOSON SYSTEMS | THE BROAD INSTITUTE, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4408990-A2 | ENGINEERED LIPASE ENZYMES, MANUFACTURE AND USE THEREOF | Anagram Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20010029015-A1 | Torsin, torsin-related genes and methods of detecting neuronal disease | THE GENERAL HOSPITAL CORPORATION (US) | 2001-10-11 | — | — | US | disclosed |
| EP-1080067-A1 | BIODEGRADABLE CORROSION INHIBITORS | THE ASSOCIATED OCTEL COMPANY LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| EP-0989995-A2 | TORSIN, TORSIN GENES, AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999059958-A1 | BIODEGRADABLE CORROSION INHIBITORS | THE ASSOCIATED OCTEL COMPANY LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998057984-A2 | TORSIN, TORSIN GENES, AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1988008875-A1 | CYCLING BIOCHIP SENSOR | THE WASHINGTON TECHNOLOGY CENTER (US) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | SLC7A5 241/4885CYP3A4 4776/4885CYP1A2 4860/4885 |
| US-20260015631-A1 | TYPE I-D CRISPR-ASSOCIATED TRANSPOSASE AND TYROSINE RECOMBINASE TRANSPOSON SYSTEMS | DCAF7, TNS4, DCTD | SLC7A5 460/4885CYP3A4 3611/4885CYP1A2 3708/4885 |
| US-12491259-B2 | Anti-variable MUC1* antibodies and uses thereof | MUC1, CD2, CD2BP2 | SLC7A5 4213/4885CYP3A4 4845/4885CYP1A2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.